Exemestane

Aromasin

Exemestane (Aromasin) is a hormonal & sexual research compound. Steroidal ('suicidal') aromatase inhibitor — permanently disables aromatase, lowering estrogen without the rebound of non-steroidal AIs.

How Exemestane works

Steroidal ('suicidal') aromatase inhibitor — permanently disables aromatase, lowering estrogen without the rebound of non-steroidal AIs.

Proposed benefits

Researched for libido, hormonal signaling and reproductive / sexual function.

Where to get Exemestane

The evidence for Exemestane

Graded by what exists behind each claim.

✅ Clinically validated

• Approved for hormone-receptor-positive breast cancer with substantial trial data, including the MA.17 and TEAM programs.

📊 Correlative data

• Used similarly to anastrozole in a male hormonal context, less commonly. Reported experience is of a smoother, less crash-prone effect, which the mechanism supports.

🧪 Theoretical / extrapolated

• A steroidal, irreversible aromatase inhibitor — it binds the enzyme permanently, so recovery requires synthesizing new enzyme.
• That predicts the two reported differences from anastrozole: no estrogen rebound on cessation, and a slower onset and offset that makes it harder to crash acutely and harder to titrate quickly.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Exemestane actually does

Aromatase is CYP19A1, a cytochrome P450 that performs three successive oxidations on the C19 methyl group of androstenedione or testosterone and ends by aromatizing the A ring — androstenedione becomes estrone, testosterone becomes estradiol. Anastrozole and letrozole are triazoles that sit in the heme pocket and coordinate the iron. They compete, reversibly, and when the drug leaves the enzyme works again. Exemestane does something categorically different.

It is a steroid, and the enzyme mistakes it for its own substrate. Exemestane is 6-methylenandrosta-1,4-diene-3,17-dione — an androstenedione skeleton with a 6-methylene group bolted on. The label's own words are that it is an irreversible, steroidal aromatase inactivator that acts as a false substrate and produces suicide inhibition US Food and Drug Administration 2024. Aromatase binds it, begins to process it, and generates a reactive intermediate that bonds covalently to the enzyme's own active site. The enzyme is not occupied; it is destroyed. Recovery requires transcribing and translating new CYP19A1 protein, not waiting for a drug to wash out.

That single structural difference explains every practical claim made about this molecule. It is why the offset is slow — the label records maximal suppression at 2 to 3 days after dosing, persisting 4 to 5 days US Food and Drug Administration 2024. It is why the drug retains activity in tumors that have progressed on a non-steroidal inhibitor: a mutation that weakens triazole binding does not necessarily stop the enzyme from processing a steroid. And it is the mechanistic basis for the community claim of “no estrogen rebound”: a covalently disabled enzyme cannot be displaced by rising substrate.

Now the part that makes exemestane a different drug in a male body, and it is the most under-reported fact on this page. Exemestane is reduced at C17 to 17-dihydroexemestane, and the label states plainly that this metabolite's androgen receptor binding is 100 times that of the parent compound US Food and Drug Administration 2024. Ariazi 2007 did the pharmacology: 17-hydroxyexemestane binds estrogen receptor alpha very weakly but binds the androgen receptor strongly, and in T47D cells at low nanomolar concentrations its effects run through the AR and parallel those of the synthetic androgen R1881, increasing AR protein. The 17β-OH group provides substantially greater interaction energy toward the AR than the parent's 17-keto group does. So the compound people take to lower estrogen also generates, in every user, a weak androgen. That is a mechanism, not a rumor, and it is the honest explanation for why exemestane's subjective profile differs from anastrozole's.

Cell, rodent, human — and where it stops

Step one, cells and enzyme kinetics. Peterson 2017 characterized hepatic oxidation and identified the cytochromes forming 17β-dihydroexemestane, and showed that nonsynonymous polymorphisms change how much of that active metabolite a given person makes. Ariazi 2007 ran MCF-7 and T47D breast cancer lines and separated two concentration regimes: at high sub-micromolar to micromolar levels the metabolite drives proliferation through ERα, and at low nanomolar levels it acts selectively through the androgen receptor.

Step two, the first human dose-finding study, which is small and very informative. Paridaens 1998 gave escalating daily oral doses of 5 to 600 mg to 27 postmenopausal women with advanced breast cancer, median treatment 13 weeks. No maximum tolerated dose was reached — there was no grade 3 or 4 toxicity anywhere in that 120-fold dose range. At 25 mg, estradiol fell to 13% of baseline, estrone to 5% and estrone sulfate to 10%. Objective response was 26% (3 complete, 4 partial), median duration 74 weeks. The label puts the same finding in population terms: maximum estrogen suppression of 85% to 95% and whole-body aromatization reduced by 98% at the 25 mg dose US Food and Drug Administration 2024.

Step three, the registered prevention trial — and it met its primary endpoint. MAP.3 Goss 2011 randomized 4,560 postmenopausal women at increased risk (median age 62.5, median Gail score 2.3%) to exemestane or placebo. At a median follow-up of 35 months there were 11 invasive breast cancers on exemestane against 32 on placebo — annual incidence 0.19% versus 0.55%, hazard ratio 0.35 (95% CI 0.18–0.70; p = 0.002), exactly the 65% relative reduction the trial was designed to detect. Adverse events occurred in 88% versus 85%, with no significant difference in fractures, cardiovascular events or other cancers over three years.

Step four, the bone substudy, which is where the cost shows up. Cheung 2012 followed 351 of those healthy women with high-resolution peripheral quantitative CT. Over two years total volumetric bone density at the distal radius fell 6.1% on exemestane against 1.8% on placebo — a difference of −4.3% (p < 0.0001); at the distal tibia 5.0% versus 1.3%. Cortical thickness fell 7.9% at the radius against 1.1%. By DEXA, lumbar spine −2.4% versus −0.5% and femoral neck −2.4% versus −0.8%. Lønning 2005 had already found the same direction in 147 women with early breast cancer: femoral neck loss of 2.72% per year against 1.48% on placebo (p = 0.024), with HDL cholesterol down 6–9% (p < 0.001).

The obstacle, and it is specific: every number above came from postmenopausal women. The population this site's readers belong to — men using an aromatase inhibitor alongside androgens — has a fundamentally different substrate load. A postmenopausal woman makes estrogen almost entirely by peripheral aromatization of adrenal androgens; a man on exogenous testosterone is presenting the enzyme with a substrate supply several times higher. Irreversible inhibition against a much larger substrate flux is a completely different pharmacological problem, and no trial has ever studied it. The only bridge the label offers is a pharmacokinetic one: a single 25 mg dose in fasted healthy men, mean age 32, produced pharmacokinetics similar to those in fasted postmenopausal women US Food and Drug Administration 2024. Same exposure. Nothing at all about the same effect.

Exemestane pharmacokinetics — how much of it actually gets in

Route: oral, and the label says to take it after a meal for a measured reason. About 42% of a radiolabeled dose is absorbed from the gastrointestinal tract, and a high-fat breakfast raises AUC by 59% and Cmax by 39% compared with the fasted state US Food and Drug Administration 2024. That is why the dosing instruction is 25 mg once daily after a meal — the registration exposure was a fed exposure, and taking it fasted delivers roughly a third less drug.

Distribution. 90% bound to plasma protein, with both albumin and alpha-1 acid glycoprotein contributing US Food and Drug Administration 2024. Note what that implies for a drug taken alongside anything else that is albumin-bound: the free fraction is small enough that displacement is plausible in principle, and has never been studied in this context.

What degrades it. CYP3A4 is the principal isoenzyme oxidizing exemestane, and it is also metabolized by aldoketoreductases US Food and Drug Administration 2024, which is the route that produces the androgenic 17-dihydro metabolite Peterson 2017. Two consequences follow directly. A strong CYP3A4 inducer — rifampicin, St John's wort, carbamazepine — should cut exposure materially, and a strong inhibitor should raise it. And because the aldoketoreductase branch is a separate route, anything shifting the balance between oxidation and reduction shifts the parent-to-androgenic-metabolite ratio, which is the ratio that determines what this drug feels like.

Half-life, and this is where the site's own card is wrong. The label gives a mean terminal half-life of about 24 hours US Food and Drug Administration 2024, not the 9 hours that circulates in enhancement discussion. Elimination is balanced: 42 ± 3% in urine and 42 ± 6% in feces over a one-week collection. But the half-life is not the number that governs the effect anyway, because the enzyme is covalently disabled — maximal suppression arrives 2 to 3 days after a dose and persists 4 to 5 days US Food and Drug Administration 2024. The pharmacodynamic half-life is the resynthesis rate of aromatase protein, and it is roughly five times the plasma half-life. That is the arithmetic behind every-other-day dosing working, and it is also why acute titration does not: a dose change today shows up in estradiol most of a week later.

Organ impairment moves it a long way. After a single 25 mg dose, AUC was approximately three times higher in both moderate to severe hepatic impairment and moderate to severe renal insufficiency US Food and Drug Administration 2024. Threefold, from a single tablet, in populations that are not rare. There is no injectable exemestane; the entire exposure question is an oral, fed, CYP3A4 question.

What would have to be true, and how you would know it was not

Four predictions with a marker, a direction and a window. The last one contradicts a claim the compound is usually sold on.

1. Estradiol should fall hard, and it must be measured on the right assay. Draw Estradiol, Sensitive (LC/MS-MS) — not the standard immunoassay, which is unreliable at the low concentrations this drug creates — at baseline and at 7–10 days, not at 48 hours, because maximal suppression takes 2 to 3 days to arrive US Food and Drug Administration 2024. From Paridaens 1998 the expectation at 25 mg is estradiol near 13% of baseline. A fall smaller than half suggests either malabsorption, a fasted-stomach dosing habit, or a substrate load high enough to outrun the enzyme kill rate.

2. Bone turnover should accelerate before density changes, and osteocalcin is how you see it early. Bone loss on this drug is not hypothetical: −4.3% total volumetric density at the distal radius over 2 years against placebo in healthy women Cheung 2012. Density itself is a two-year read-out; Osteocalcin, a formation marker, moves in months. Baseline and 16 weeks. Prediction: osteocalcin rises, signaling accelerated remodeling, well before any DEXA would show anything.

3. HDL should fall and the rest of the panel should not. Lønning 2005 found a selective 6–9% reduction in HDL cholesterol (p < 0.001) with a modest apolipoprotein A1 fall and no meaningful change in total cholesterol, LDL or triglycerides, which the label repeats US Food and Drug Administration 2024. So a Lipid Panel at baseline and 12 weeks should show a specific, isolated HDL drop. If LDL and triglycerides move too, something other than the aromatase inhibitor is driving it.

4. The prediction that cuts against it: exemestane is the weaker estrogen suppressor of the modern inhibitors, not the stronger one. Bertelsen 2024 ran the head-to-head nobody had done: 79 postmenopausal breast cancer patients, intra-patient crossover, letrozole 2.5 mg against exemestane 25 mg. Letrozole suppressed estrone and estradiol to 0.2 and 0.4 pmol/L; exemestane to 1.8 and 0.6 pmol/L, and crossing over from letrozole to exemestane let estrone rise back to 1.4 pmol/L. The authors' conclusion is that letrozole produces a more profound suppression. Anyone choosing exemestane on the belief that irreversible means stronger has the pharmacology backwards: irreversible means slower on and slower off, which is a different and often more useful property. If your sensitive estradiol on exemestane sits higher than it did on anastrozole at an equivalent point, that is the expected result, not a bad batch.

For men using this off-label alongside androgens, add Total Testosterone, SHBG and LH & FSH to the same draw. The mechanism predicts that crushing estradiol releases hypothalamic negative feedback and pushes LH up in an intact axis — and that the androgenic 17-dihydro metabolite Ariazi 2007 is invisible to every one of those assays, because no clinical laboratory measures it.

What nobody has tested yet

Nobody has measured 17-dihydroexemestane in a man. The label states the metabolite binds the androgen receptor 100-fold more strongly than the parent US Food and Drug Administration 2024 and Ariazi 2007 shows it behaving like an androgen at low nanomolar concentrations. Every person taking exemestane makes it, the amount made varies with aldoketoreductase and CYP genotype Peterson 2017, and there is no published measurement of its concentration in a male user, let alone a correlation with how the drug feels. An LC-MS/MS assay for parent and metabolite, run in twenty men at steady state alongside a sensitive estradiol, would produce genuinely new information about a drug that has been approved since 1999.

Nobody has tested the rebound claim. The whole argument for exemestane over anastrozole in this context is that a covalently inactivated enzyme cannot rebound on withdrawal. That is a sound mechanistic prediction and nobody has run the withdrawal experiment: sensitive estradiol every 48 hours for three weeks after stopping, exemestane against anastrozole, in the same people. Aromatase resynthesis rate in human adipose tissue has never been measured in vivo, and this is the cheapest way to infer it.

Nobody knows the dose-response in the presence of a large androgen substrate load. The 25 mg dose was fixed in women whose entire estrogen supply comes from adrenal precursors Paridaens 1998, and the phase I study went to 600 mg without reaching a maximum tolerated dose. Whether the enzyme-kill rate saturates before the substrate supply does, in a man on supraphysiologic testosterone, is an unanswered kinetic question with a practical answer available from a simple dose-ranging study using sensitive estradiol as the endpoint.

Exemestane — its own safety story, not its class's

The bone cost is the real one, it is measured, and it happens in healthy people. Cheung 2012 is the study to know because its subjects were healthy postmenopausal women, not cancer patients: two years of 25 mg daily produced a 4.3% greater loss of total volumetric bone density at the distal radius than placebo, a 6.8% greater loss of cortical thickness there, and losses at the tibia, lumbar spine, hip and femoral neck that were all significant. The authors' conclusion was that exemestane worsens age-related bone loss. The label's own figures are −3.1% lumbar spine and −4.2% femoral neck US Food and Drug Administration 2024. Anyone using this for more than a few months without calcium, vitamin D, loading exercise and a baseline DEXA is accepting a documented cost without measuring it.

The lipid effect is small, selective, and points the wrong way. HDL falls 6–9% with a modest apolipoprotein A1 fall and nothing else on the panel moving Lønning 2005 US Food and Drug Administration 2024. On its own that is minor. Stacked with oral androgens, which suppress HDL far harder, it is additive in a direction nobody wants.

What the trials actually reported as side effects. Against tamoxifen in early breast cancer the label lists hot flushes 21% vs 20%, fatigue 16% vs 15%, arthralgia 15% vs 9%, headache 13% vs 11%, insomnia 12% vs 9%, increased sweating 12% vs 10% US Food and Drug Administration 2024. Joint pain is the one with a real excess, and it is the most common reason people stop an aromatase inhibitor of any kind.

Liver and kidney impairment triple the exposure from an unchanged tablet. AUC was about three times higher in moderate to severe hepatic impairment and in moderate to severe renal insufficiency after a single 25 mg dose US Food and Drug Administration 2024. No dose adjustment is specified, which is a statement about the drug's wide therapeutic window — the phase I study reached 600 mg without a dose-limiting toxicity Paridaens 1998 — not a statement that the exposure difference is imaginary.

The two things this page will not tell you. Exemestane's approved indications are in postmenopausal women with breast cancer; every efficacy number here comes from that population. And crushing estradiol is not a goal in itself in anyone. Estrogen in men maintains bone, lipids, libido and joint comfort, and the failure mode of this class in male use is over-suppression — joint pain, low mood, flat libido and accelerating bone loss — which looks exactly like the failure mode of not using it at all, and can only be told apart with a sensitive estradiol result.

Sources read for this page

• Paridaens R, Thomas J, Wildiers J, Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A, Lanzalone S, de Belder K. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.. Anticancer Drugs 1998 · PMID 9823425
• Ariazi EA, Leitão A, Oprea TI. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.. Mol Cancer Ther 2007 · PMID 17989318
• Goss PE, Ingle JN, Alés-Martínez JE. Exemestane for breast-cancer prevention in postmenopausal women.. N Engl J Med 2011 · PMID 21639806
• Cheung AM, Tile L, Cardew S. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.. Lancet Oncol 2012 · PMID 22318095
• Peterson A, Xia Z, Chen G. In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane.. Pharmacol Res Perspect 2017 · PMID 28603633
• Bertelsen BE, Almås B, Fjermeros K. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.. Breast Cancer Res Treat 2024 · PMID 38649619
• Lønning PE, Geisler J, Krag LE. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.. J Clin Oncol 2005 · PMID 15983390
• US Food and Drug Administration. AROMASIN (exemestane) tablets, for oral use - full prescribing information.. FDA approved labeling, revision 2024

Exemestane — safety, predicted from mechanism

Exemestane — interference & stacking

Bloodwork to run alongside Exemestane

Baseline first, then again at 8–12 weeks.

The TRT Monitoring panel covers these in one order — 9 markers, $198.45 with the discount applied.

Check results you already have → · All 103 markers A–Z

Exemestane — frequently asked questions

Exemestane inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Exemestane is used for

Exemestane appears under 1 goal in the goal router.

Related Hormonal & Sexual compounds

← Explore the full Protocol Vault

↑ Back to on this page